Innovative Therapies | Transforming Lives

Immuno-Oncology

Disruptive Technology to Turn a Cold Tumor Hot

Kineta is developing novel immune stimulating drugs to turn cold tumors hot. Cancer remains one of the leading causes of death in the United States and worldwide. The evolution of immunotherapies has created new treatment options for some types of cancer but the overall patient response rates remain relatively low.

Checkpoint inhibitors only enable existing memory T cell populations and have low complete response rates in the clinic of approximately 20-30% with checkpoint monotherapy. All immunotherapies require the presence of tumor specific T cells that are very limited or not present in many patients. Novel new immunotherapies are needed to improve long term survival in cancer patients.

Kineta is developing a disruptive technology focused on immune stimulation to turn cold tumors hot. Small molecule drugs that target innate immune pathways like RIG-I can be effective but have been previously unexploited for drug discovery.